Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19192738 | 0.89 | ALDH1A1 (0.58) | ALDH1A1KDM4EPOLBTDP1DDR1 | |
| SCHEMBL27824318 | 0.89 | ALDH1A1 (0.58) | ALDH1A1KDM4EPOLBTDP1DDR1 | |
| Hydrochloric Acid SCHEMBL3567586 | 0.87 | ALDH1A1 (0.57) | ALDH1A1KDM4EPOLBTDP1DDR1 | |
| SCHEMBL18922209 | 0.87 | ALDH1A1 (0.57) | ALDH1A1KDM4EPOLBTDP1DDR1 | |
| SCHEMBL6594936 | 0.87 | IP6K1 (0.54) | ALDH1A1KDM4EPOLBTDP1IP6K1 | |
| SCHEMBL9939410 | 0.85 | CHKA (0.57) | ALDH1A1KDM4EPOLBTDP1DDR1 | |
| SCHEMBL3565908 | 0.84 | HDAC6 (0.47) | ALDH1A1KDM4EPOLBTDP1DDR1 | |
| SCHEMBL18775267 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KDM4EADORA1HDAC6EPHX2 | |
| Hydrochloric Acid SCHEMBL28830570 | 0.84 | CYP2D6 (0.55) | ALDH1A1KDM4EPOLBTDP1IP6K1 | |
| SCHEMBL13529185 | 0.83 | DDR1 (0.53) | ALDH1A1KDM4EDDR1ADORA1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-1840122-B1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | SUN PIAOYANG (CN) | 2013-08-28 | — | — | EP | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-8183242-B2 | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | Sun, Piaoyang (CN) | 2012-05-22 | — | — | US | disclosed |
| CN-1972917-B | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | PIAOYANG SUN | 2010-08-25 | — | — | CN | disclosed |
| US-20080312251-A1 | Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2008-12-18 | — | — | US | disclosed |
| EP-1840122-A1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | Sun, Piaoyang (CN) | 2007-10-03 | — | — | EP | disclosed |
| CN-1939910-A | Amino-metadiazine compound and its salt, its preparation and pharmaceutical use | SUN PIAOYANG (CN) | 2007-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | XDH, CYP2B6, COX6B1 | ALDH1A1 1279/4885KDM4E 1649/4885POLB 2449/4885 |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ALDH1A1 1279/4885KDM4E 1649/4885POLB 2449/4885 |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ALDH1A1 1279/4885KDM4E 1649/4885POLB 2449/4885 |
| US-20080312251-A1 | Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof | DPYD, PKN2, TYMP | ALDH1A1 2443/4885KDM4E 922/4885POLB 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.